Levothyroxine: A black swan? [BE/BA News]

posted by DavidManteigas – Portugal, 2017-11-27 18:53 (2285 d 04:12 ago) – Posting: # 18014
Views: 7,635

There isn't any biological background that might explain this issue? Or problems during manufacturing? This is really awkward... the CI and point estimate are far more "perfect" than I am used to see. In fact, in full replicate studies, I've seen reference drugs "performing" poorly when compared with single administrations of themselves... Is the dose-toxicity so sensible for this drug that event the narrower limits does not apply in this case? Did a quick search and haven't find any study reporting the dose-response of this drug

Complete thread:

UA Flag
Activity
 Admin contact
22,916 posts in 4,807 threads, 1,645 registered users;
33 visitors (0 registered, 33 guests [including 10 identified bots]).
Forum time: 23:05 CET (Europe/Vienna)

Nothing shocks me. I’m a scientist.    Harrison Ford (as Indiana Jones)

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5